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Abstract: The growth of many soft tissue sarcomas is dependent on aberrant growth factor 
signaling, which promotes their proliferation and motility. With this in mind, we evaluated 
the effect of sorafenib, a receptor tyrosine kinase inhibitor, on cell growth and apoptosis 
in sarcoma cell lines of various histological subtypes. We found that sorafenib effectively 
inhibited cell proliferation in rhabdomyosarcoma, synovial sarcoma and Ewing’s sarcoma 
with IC50 values 5 μM. Sorafenib effectively induced growth arrest in rhabdomyosarcoma 
cells, which was concurrent with inhibition of Akt and Erk signaling. Studies of ligand-induced 
phosphorylation of Erk and Akt in rhabdomyosarcoma cells showed that insulin-like growth 
factor-1 is a potent activator, which can be blocked by treatment with sorafenib. In vivo sorafenib 
treatment of rhabdomyosarcoma xenografts had a signiﬁ  cant inhibitory effect on tumor growth, 
which was associated with inhibited vascularization and enhanced necrosis in the adjacent tumor 
stroma. Our results demonstrate that in vitro and in vivo growth of rhabdomyosarcoma can be 
suppressed by treatment with sorafenib, and suggests the possibilities of using sorafenib as a 
potential adjuvant therapy for the treatment of rhabdomyosarcoma.
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Introduction
The recent identiﬁ  cation of broad range multikinase inhibitors has raised the possibility 
for potential targeted therapies against tumors which display dependency on growth 
factor-mediated signaling. Many cancer cells utilize numerous receptor tyrosine kinases 
such as platelet-derived growth factor receptor-β (PDGFRβ), c-KIT and vascular 
endothelial growth factor receptor (VEGFR), to transmit growth signals from the cell 
surface to the intra cellular milieu to mediate numerous biological responses (Amit et al 
2007; Do et al 2007). Two of the most characterized receptor tyrosine kinase-mediated 
signaling cascades are the Ras/Raf/MEK/Erk and Ras/PI3K/Akt pathways which 
are involved in promoting cell proliferation (Chambard et al 2007) and cell survival 
(Downward 1998; Xue et al 2000) respectively. Receptor tyrosine kinases induced 
activation of the Ras/Raf/MEK/Erk pathway promotes cell proliferation by inducing 
the activating phosphorylation and nuclear localization of Erk, which promotes cell 
cycle progression by mediating transcriptional activation of the cyclin D1 gene and by 
promoting the disassociation of E2F1 from the negative regulation of Rb (Chambard 
et al 2007). In contrast, the activation of Akt promotes cell survival as opposed to 
proliferation. Phosphorylated Akt promotes stabilization of HDM2, the negative regu-
lator of p53, promotes sequesterization of the pro apoptotic Bad protein and promotes 
enhanced protein translation via the mTOR pathway (Datta et al 1997; del Peso et al 
1997; Ashcroft et al 2002; Faivre et al 2006). Crosstalk also exists between the Erk and 
Akt pathways via MEK (Misra and Pizzo 2004; Myhre et al 2004; Merighi et al 2006), OncoTargets and Therapy 2008:1 68
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thus providing further levels of regulation. In light of their 
importance in cancer, both pathways serve as useful molecular 
targets for the development of targeted therapies.
BAY 43-9006/Sorafenib/Nexavar® (hereafter referred 
to as sorafenib), is a small molecule, multi kinase inhibitor. 
Although initially identiﬁ  ed as a Raf inhibitor, subsequent 
molecular studies have shown that it is also a potent inhibitor 
of several receptor tyrosine kinases involved in tumor 
progression, including VEGFR-2 and -3, PDGFRβ, c-KIT 
and FLT-3 (Lowinger et al 2002; Wilhelm et al 2004, 2006). 
Sorafenib was shown to effectively block the Raf/MEK/Erk 
signaling pathway and to have broad anti-tumor activity in 
preclinical studies (Karasarides et al 2004; Wilhelm et al 
2004; Panka et al 2006).
The efﬁ  cacy of sorafenib in clinical trials for the treatment 
of solid tumors has been most favorable for renal cell carcinoma 
(Ratain et al 2006; Bracarda et al 2007; Escudier et al 2007; 
Llovet et al 2007). In a phase III trial, including patients 
with advance clear-cell renal-cell carcinoma, treatment with 
sorafenib alone as second-line therapy prolonged the pro-
gression-free survival, resulting in 74% (sorafenib) and 53% 
(placebo) stable disease, and a disease control rate of 62% 
(sorafenib) and 37% (placebo) (Escudier et al 2007). Another 
phase III clinical trial, including patients with advanced hepa-
tocellular carcinoma with no previous systemic treatment, 
showed prolonged survival in patients receiving treatment 
with sorafenib versus placebo, resulting in a 44% increase in 
overall survival (Llovet et al 2007).
Clinical trials evaluating the activity of sorafenib in soft 
tissue sarcomas have been conducted. A phase II trial on 
advanced gastrointestinal stromal tumors (GIST) that express 
c-Kit and with resistance to imatinib and sunitinib, resulted in 
14% partial response, 62% stable disease, 24% progressive 
disease, and a disease control rate of 76% (Wiebe et al 2008). 
On non-GIST sarcomas, a phase II trial showed a 15% and 5% 
response in angiosarcomas and leiomyosarcomas, respectively 
(D’Adamo et al 2007). It was recently reported that malignant 
peripheral nerve sheath tumor (MPNST) cell lines are sensitive 
to sorafenib, whereas liposarcoma cell lines are resistant to 
treatment with sorafenib (Ambrosini et al 2008). However, a 
phase II study of sorafenib in patients with leiomyosarcoma, 
malignant ﬁ  brous histiocytoma (MFH), MPNST, angiosarcoma 
and synovial sarcoma, resulted in a 14% and 6% response 
rate in patients with angiosarcoma and leiomyosarcoma, 
respectively, but only minor responses were observed in 
patients with MPNST and synovial sarcoma (Maki et al 
2008). Another phase II study, in patients with advanced soft 
tissue sarcomas, did not result in RECIST response. However, a 
notable progression free survival was observed in patients with 
angiosarcoma and hemangiopericytoma (Ryan et al 2008).
In this study we investigate and evaluate the effect of 
sorafenib in 13 soft tissue sarcoma cell lines of four different 
histological subtypes in vitro and in tumor xenografts.
Materials and methods
Cell lines
Panels of 13 sarcoma cell lines (three rhabdomyosarcomas, 
two synovial sarcomas, four Ewing’s sarcomas, and four 
osteosarcomas) were analyzed. Rhabdomyosarcoma 
cell lines RH30, RD, and RMS were obtained from 
Molecular Cytogenetics Unit at Institute of Cancer Research 
(Sutton, UK). The synovial sarcoma cell line CME-1 was 
obtained from the Instituto Nazionale per lo Studio e la 
Cura dei Tumori (Milan, Italy). Ewing’s sarcoma cell lines 
SK-ES-1, SK-N-MC, RD-ES and Lap 35, and osteosarcoma 
cell lines IOR-OS9 and IOR-OS10 were obtained from the 
Laboratory of Oncologic Research, Orthopaedic, Rizzoli 
Institute (Bologna, Italy). Osteosarcoma cell lines SAOS2 
and U2OS were obtained from ATCC culture collection. All 
cell lines grow as adherent cultures and were passaged in opti-
mized mediums supplemented with 100 units/ml penicillin, 
100 μg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, 
USA) and 10%–20% heat inactivated fetal bovine serum 
(FBS) (High clone III, HyClone, Cramlington, UK). Infor-
mation about the cell lines, their genetic and phenotypic 
characteristics is provided in Table 1.
Drugs
Sorafenib was kindly provided by Bayer Pharmaceuticals 
Corporation (West Haven, CT, USA). For in vitro assays, a 
10 mM stock was prepared in dimethyl-sulfoxide (DMSO) 
(Sigma-Aldrich), newly prepared before the initiation of 
each assay, from which working solutions were carefully set 
immediately before use according to desired concentrations. 
Sorafenib is light sensitive in solution and was therefore kept 
in dark during the course of the experiments. For in vivo 
studies, sorafenib was newly prepared in a vehicle composed 
of Cremophor EL/ethanol/water (12.5%–12.5%–75%) for 
daily per oral administration.
In vitro cytotoxicity assays
Cells were seeded in 96 well plates and incubated overnight to 
become adherent before treatment with sorafenib. Sorafenib 
was added to ﬁ  nal concentrations of 0–5 μM. Cell viability 
and proliferation was determined after 48 hrs by the capability 
of viable cells to cleave tetrazolium salt into formazan OncoTargets and Therapy 2008:1 69
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(WST-1 Assay, Roche, Basel, Switzerland), according to 
manufacturer’s instructions. Percentage of viability after drug 
administration was calculated in relation to untreated control 
(100% viability). Each assay was repeated a minimum of 
four times to conﬁ  rm trends and the average concentration at 
which 50% of the cells are inhibited (IC50) determined.
Immunoﬂ  uorescence
Cells were plated in eight well chamber slides (Falcon, BD 
Biosciences, San Jose, CA, USA) and allowed to adhere over 
night. Cells were ﬁ  xed in ice cold acetone/methanol (1:1) for 
15 minutes at −20 °C, permebealized in PBS/0.25% Triton-X 
100 and blocked in blocking buffer (2% BSA, 5% glycerol, 
0.2% Tween 20 and 0,02% Na-azide). Cells were incubated 
with primary antibody overnight at 4 °C, washed with 
PBS/0.05% Tween 20, incubated with secondary antibody 
for 45 minutes (anti-rabbit DyLight Alexa 488 FITC; Pierce 
Biotechnology Inc., Rockford, IL, USA or anti-mouse Texas 
Red; Vector laboratories, Burlingame, CA, USA), washed and 
mounted with Vectashield mounting media containing DAPI 
(Vector Laboratories). Cells were stained with the following 
antibodies: IGF1Rβ (1:20, Cell Signaling Technology Inc., 
Danvers, MA, USA), VEGFR2 (1:50, Cell Signaling Tech-
nology Inc.,), PDGFRβ (1:50, Sigma-Aldrich), FLT-3 (1:50, 
Cell Signaling Technology Inc.,) and c-KIT (1:50, Biosource-
Invitrogen, Carlsbad, CA, USA).
FACS analysis
Cells were seeded and incubated over night to become 
adherent before treatment with sorafenib. Sorafenib was 
added to ﬁ  nal concentrations of 0–5 μM for 48 hrs.
To estimate DNA fragmentation by apoptosis, cells were 
stained with propidium iodide (PI) and ﬂ  oating and attached 
cells were collected by trypsinization and ﬁ  xed in 70% ice cold 
ethanol for 24 hrs. Cells were stained with 50 μg/ml PI supple-
mented with recombinant 100 μg/ml RNAse for 45 minutes 
at room temperature and DNA fragmentation by apoptosis 
was analyzed as the sub-G1 cell fraction.
For Annexin V staining, cells were harvested by 
trypsinisation and stained with Annexin V apoptosis 
detection kit (Sigma-Aldrich) according to manufacturer’s 
protocol, and analyzed by FACS, for detection of cells during 
early phases of apoptosis.
Western blot and phosphorylation 
analysis
Cells were seeded and incubated over night to become adherent, 
followed by starvation in serum deﬁ  cient medium for 24 hrs 
prior to substitution with FBS-enriched medium. Sorafenib 
was added to ﬁ  nal concentrations of 0–5 μM 30 minutes before 
serum stimulation. Cells were then harvested in 2x loading 
buffer, containing 10% β-mercaptoethanol, sonicated, heated 
for 10 minutes at 90 °C and the cell lysates were separated 
by SDS-PAGE (Invitrogen) on 4%–12% gradient gels under 
denaturing conditions and transferred onto PVDF membranes 
(Amersham, Buckinghamshire, UK). After blocking in 
5% BSA (Sigma-Aldrich), the PVDF ﬁ  lters were incubated 
over night at 4 °C with the primary antibody anti-phospo-Erk 
or anti-phospho-Akt (Cell Signaling Technology Inc.), total 
AKT or total ERK (Sigma-Aldrich). After a series of washes 
in PBS/0.1% Tween 20 (PBS-T), the membranes were incu-
bated 1 hr with secondary antibody conjugated to horseradish 
Table 1 IC50 of sorafenib in soft tissue sarcoma cell lines
Cell line Genetics IC50 (μM Sorafenib)
Rhabdomyosarcoma RMS (a) PAX3/7-FKHR 3.9
Rhabdomyosarcoma RH30 (a) PAX3/7-FKHR 5
Rhabdomyosarcoma RD (e) 22q- 4.5
Synovial sarcoma SYO-1 SS18/SSX2 2.4
Synovial sarcoma CME-1 SS18/SSX2 2.8
Ewing’s sarcoma SK-N-MC EWS-FLI-1 (t1) 2.4
Ewing’s sarcoma SK-ES-1 EWS-FLI-1 (t2) 5
Ewing’s sarcoma RD-ES EWS-FLI-1 (t2) 3
Ewing’s sarcoma LAP-35 EWS-FLI-1 (t2) 5
Osteosarcoma SAOS2 complex 5
Osteosarcoma U2OS complex 5
Osteosarcoma IOR-OS9 complex 5
Osteosarcoma IOR-OS10 complex 5OncoTargets and Therapy 2008:1 70
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peroxidase (Pierce Biotechnology Inc., Rockford, IL, USA). 
Filters were subsequently washed in PBS-T and developed 
using chemiluminescence western blotting detection reagents 
(Pierce Biotechnology Inc.,).
Activation of MAPK and AKT 
by ligand stimulation
Cells were seeded and incubated over night to become 
adherent, followed by starvation in serum deﬁ  cient medium 
for 24 hrs prior to treatment with 0–5 μM sorafenib for 4 hrs, 
followed by ligand treatment (50 ng/ml) for 30 minutes. The 
cells were then harvested in 2x loading buffer and the lysates 
were separated by SDS-PAGE, as described above. Cells 
were stimulated with FLT-3, SCF, VEGF, PDGF (Immuno 
Tools, Friesoythe, Germany), and insulin-like growth factor 
(IGF) (Sigma-Aldrich).
Xenografts and sorafenib treatment
The described animal studies were approved by the ethics 
committee Stockholms Norra Djurförsöksetiska Nämnd 
(N113/04).
BALB/c SCID mice (∼8 weeks old, 20–30 g) were 
obtained from and the animal experiments were carried out at 
the Microbiology and Tumor biology Center (MTC) Animal 
Facility, Karolinska Institutet, Sweden. The animals were 
cared for by trained animal keepers and the health status of 
the animals was supervised carefully.
Each mouse (6 per group) was inoculated subcutane-
ously with 5 × 106 cells resuspended in 100 μl matrigel (BD 
Biosciences, San Jose, CA, USA) in the right ﬂ  ank. Treat-
ment with sorafenib was initiated when tumors were palpable 
(day 8 after inoculation) by daily per oral administration of 
sorafenib (40, 60, 80 mg/kg body weight) or placebo (vehicle 
only) for a total of 7 days. Tumor dimensions were recorded 
twice weekly. At the end point of the experiment, mice 
were euthanized by cervical dislocation and each tumor was 
excised and ﬁ  xed in formalin. Tumor volumes were calcu-
lated using the equation (l × w2)/2, where l and w represent 
the largest and smallest dimensions at each measurement. 
The effect of drug treatment on tumor growth was analyzed 
statistically with individual group comparison and evaluated 
with independent samples T-test by SPSS 15.0 (SPSS Inc., 
Chicago, IL, USA).
Preparation of parafﬁ  n tumor tissue 
sections
Animals were euthanized by cervical dislocation and the 
tumor tissue was excised and ﬁ  xed in formalin and embedded 
in parafﬁ  n. The tumors were cut in 4 μm sections and the 
sections were placed on object slides. Parafﬁ  n was cleared 
with xylene and the tumor sections were re-hydrated and 
stained with Mayers hematoxylin and eosin.
Immunohistochemistry of parafﬁ  n 
tumor tissue sections
Sections were studied immunohistochemically, using 
the AvidinBiotin Complex method (VECTASTAIN Elite 
ABC Kit; Vector Laboratories). Heat-induced epitope 
retrieval with citrate buffer (pH 6) was performed for 
these sections via microwave oven at 98 °C for 20 minutes, 
or pronase for 15 minutes. Endogenous peroxidase activity 
was blocked with H2O2. Peroxidase activity was developed 
with 3-3-diaminobenzidine (Sigma-Aldrich) to obtain a 
brown end product. Representative sections were stained 
with the following antibodies: Ki-67 (MIB-1, 1:500, DAKO, 
Glostrup, Denmark) and PECAM-1 (M-20, 1:50, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA).
Results
Sorafenib inhibits cell proliferation 
in synovial sarcoma, rhabdomyosarcoma 
and Ewing’s sarcoma cell lines at clinically 
relevant doses
Rhabdomyosarcomas, synovial sarcomas, osteosarcomas 
and Ewing’s sarcomas typically express multiple receptor 
tyrosine kinases all of which are potential targets for 
inhibition by sorafenib (Ricotti et al 1998; Handa et al 
2000; Landuzzi et al 2000; Zhang et al 2000; Gordon et al 
2001; Lowinger et al 2002; Kawai et al 2004; Tamborini 
et al 2004; Gee et al 2005; Kreuter et al 2006; Armistead 
et al 2007; Do et al 2007). With this in mind, we evaluated 
the anti-proliferative effect of sorafenib on a panel of soft 
tissue tumor cell lines. Cells were exposed to increasing 
concentrations of sorafenib for 48 hrs with values greater 
than 5 μM considered beyond the scope of clinical relevance. 
The ability of sorafenib to inhibit cell proliferation was 
determined by WST-1 assay, a colorimetric assay that mea-
sures the metabolic activity which correlates to cell viability. 
We found that sorafenib inhibited cell growth in a dose 
dependent manner in all rhabdomyosarcoma (3 of 3); in all 
synovial sarcoma (2 of 2), and in 50% of Ewing’s sarcoma 
cell lines (2 of 4), with IC50 values below 5 μM (Table 1). 
All four osteosarcoma cell lines were refractive to sorafenib 
treatment within these concentration ranges (Table 1). Since 
all three rhabdomyosarcoma cells responded we chose these OncoTargets and Therapy 2008:1 71
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cell lines for further investigations. Microscopic analysis 
of cells showed a dose dependent decrease in cell numbers 
in sorafenib-treated cells (Figure 1A). We evaluated the 
induction of apoptosis following treatment with sorafenib in 
the rhabdomyosarcoma cell line RMS by annexin V staining, 
as an indicator of early apoptosis and propidium iodide 
staining for DNA fragmentation. Treatment with sorafenib 
for 48 hrs resulted only in a moderate increase in both 
annexin V staining and DNA cleavage when compared to 
mock-treated control cells (Figures 1B–C). Taken together 
our data demonstrates that sorafenib primarily induces growth 
arrest as opposed to apoptosis in rhabdomyosarcoma cells.
Sorafenib inhibits Erk and Akt activation 
in rhabdomyosarcoma cells
In order to gain further insight into the downstream effects 
of sorafenib in rhabdomyosarcoma, we analyzed the 
activation of Erk and Akt in response to serum stimulation 
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Figure 1 Effect of sorafenib on cell cycle in alveolar rhabdomyosarcoma (RMS) cells. A) Sorafenib inhibits proliferation of RMS in a dose dependent manner. Rhabdomyosarcoma 
cells were cultured and treated with 0–5 μM sorafenib for 48 hrs and visualized using light microscopy. B) Estimation of sub-G1 content. Cells were treated as above and 
sub-G1 fraction of cells was determined by PI staining and FACS analysis. C) Annexin V staining of sorafenib-treated RMS cells. Cells were treated with sorafenib as above 
and the level of Annexin V staining was determined by FACS analysis.
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in the absence and presence of sorafenib. Western blot 
analysis of Erk and Akt phosphorylation showed that 
sorafenib effectively inhibited serum-induced phosphory-
lation in a dose dependent manner (Figure 2A). Sorafenib 
totally inhibited Erk and Akt phosphorylation at 3 μM 
without affecting the total levels. We investigated the 
effect of treatment with sorafenib on the time dependent 
inhibition of Erk and Akt activation following serum 
stimulation. Serum-induced phosphorylation of Erk reached 
maximum phosphorylation 10 min post-serum addition 
with levels rapidly decreasing thereafter, whereas Akt 
phosphorylation displayed a slower induction proﬁ  le with 
levels rising over the period of the time course (Figure 2B). 
Pretreatment with sorafenib effectively blocked both Erk 
and Akt phosphorylation following serum stimulation. 
Taken together our results demonstrate that sorafenib 
effectively blocks serum-induced Erk and Akt activation 
in rhabdomyosarcoma cells.
Sorafenib inhibits IGF-1-induced Erk 
and Akt signaling in rhabdomyosarcoma 
cell lines
Sorafenib has been shown to inhibit Erk and Akt phos-
phorylation in response to activation of tyrosine kinase 
receptors (Wilhelm et al 2004; Sridhar et al 2005; Adnane 
et al 2006; Flaherty 2006; Tong et al 2006; Yu et al 2006; 
Zhong and Bowen 2007; Ammoun et al 2008). Analysis 
of receptor tyrosine expression showed the presence of 
high levels of c-KIT, PDGFRβ, FLT-3 and VEGFR2 in all 
rhabdomyosarcoma cell lines (Figure 3, Table 2). We also 
included IGF-1R since over expression has been previously 
observed in rhabdomyosarcoma (El-Badry et al 1990; Minniti 
et al 1992, 1994; Shapiro et al 1994). High levels of IGF-1R 
expression was observed in all rhabdomyosarcoma cell lines 
as indicated by high levels of cell surface staining. Next we 
evaluated Erk and Akt phosphorylation in response to ligand 
addition. Surprisingly, ligand stimulation induced by SCF, 
VEGF, PDGF and FLT-3 only induced weak phosphorylation 
of Erk and Akt in all three rhabdomyosarcoma cell lines when 
compared with growth serum. Since our previous data showed 
that IGF-1R is expressed at high levels in rhabdomyosarcoma 
cells, we analyzed the effect of IGF-1 stimulation on Erk 
and Akt phosphorylation in the presence and absence of 
sorafenib. In contrast to the previous ligands, IGF-1 was a 
potent inducer of Erk and Akt phosphorylation in all cell lines 
with IGF-1 inducing Erk and Akt phosphorylation to levels 
similar to that observed in serum stimulated cells. Treatment 
with 5 μM sorafenib effectively blocked IGF-1-mediated 
activation of Akt and Erk in RMS cells (Figure 4A). 
Sorafenib also blocked IGF-1-mediated activation of Erk 
in RH30 and RD cells (Figures 4B and C), however, Akt 
phosphorylation was still observed (Figures 4B and C). Our 
results show that IGF-1 is a potent activator of Erk and Akt 
in rhabdomyosarcoma RMS cells which can be effectively 
blocked by sorafenib.
Sorafenib inhibits IGF-1-induced cell 
growth in rhabdomyosarcoma cell lines
To determine if sorafenib inhibited growth induced by 
IGF-1 stimulation, we preformed WST-1 cell proliferation 
assays on rhabdomyosarcoma cells which were grown in 
the presence and absence of sorafenib and with or without 
serum or IGF-1. Cells were starved and then allowed to grow 
in the presence or absence of serum or IGF-1, followed by 
treatment with 5 μM sorafenib over a 48 hrs period. Inhibition 
of cell proliferation by sorafenib was normalized to each of 
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Figure 2 Sorafenib inhibits Erk and Akt activation in alveolar rhabdomyosarcoma 
(RMS) cells. A) RMS cells were starved for 24 hrs, treated with 0–5 μM sorafenib for 
4 hrs and simulated with serum for 10 minutes. Cells were harvested for western 
blotting by direct lysis in loading buffer. Levels of phosphorylated Erk and Akt were 
detected using phosphor speciﬁ  c antibodies. Levels of total Erk and Akt were used 
as a loading control. B) RMS cells were serum starved for 24 hrs, pre-treated with 
5 μM sorafenib and stimulated with serum for the indicated time points. Levels of 
phosphor Erk and Akt were detected as above.OncoTargets and Therapy 2008:1 73
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the growth conditions. We found that sorafenib inhibited 
cell growth in normal conditions (as mentioned above) and 
to a greater extent in starved conditions and in cells grown 
in the presence of IGF-1 (Figure 5). Our data shows for the 
ﬁ  rst time that sorafenib can inhibit cell proliferation induced 
by IGF-1 in rhabdomyosarcoma cells.
Sorafenib inhibits tumor growth
and vascularization in rhabdomyosarcoma 
xenografts
To evaluate the antiproliferative effect of sorafenib in vivo, 
rhabdomyosarcoma xenografts were established in SCID 
mice, as described in materials and methods. Analysis of 
RMS xenograft tumors in placebo-treated mice showed the 
presence of large tumors, which appeared highly vascularized. 
There was a signiﬁ  cant difference in tumor volume (at least 
four times as large) in sorafenib-treated mice when compared 
with placebo (Figure 6A). Upon macroscopic examina-
tion of the excised tumors, sorafenib-treated tumors were 
RMS
IGF-1Rβ
VEGF-R2
FLT-3
c-KIT
PDGF-Rβ
RH30
α- FITC (Green)
α- Texas Red (Red)
DAPI (Blue)
RD
DAPI (Blue)
Figure 3 Expression of receptor tyrosine kinases in rhabdomyosarcoma cells. Rhabdomyosarcoma cells (RMS, RH30, and RD) were cultured in chamber slides, ﬁ  xed and 
incubated with antibodies against the indicated receptor tyrosine kinase. Receptor tyrosine expression was visualized using the appropriate ﬂ  uorescent conjugated secondary 
antibody.
Table 2 Expression of RTKs in soft tissue sarcoma cell lines
Cell line IGF-1R VEGF-R2 FLT -3 PDGF-Rβ c-KIT
RMS (a) ++ + + +
RH30 (a) ++ + + +
RD (e) ++ + + +
SYO-1 ++ + + +
CME-1 − nd nd ++
SK-N-MC + nd nd −+
SK-ES-1 + + + +/− +
RD-ES + nd nd −+
LAP-35 + nd nd + +/−
+: receptor tyrosine kinase is expressed.
−: receptor tyrosine kinase is not expressed.
nd: not determined.
typically smaller and poorly developed, which was reﬂ  ected 
in the administered dose. Hematoxilin and eosin staining of 
tumor tissue showed that histology of the untreated tumors 
(Figure 6B, upper left panel) had a classical alveolar structure OncoTargets and Therapy 2008:1 74
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typical of RMS rhabdomyosarcoma, consisting of clusters of 
tumor cells surrounded by collagenous ﬁ  brovascular tissue 
(septa, S). Sorafenib-treated tumors (Figure 6B, upper right 
panel) displayed high levels of necrotic areas (N) around the 
septa, and were characterized by the presence of necrotic cells 
(picnotic, dark purple).
To assess cell proliferation in these tumors, parafﬁ  n 
embedded sections were stained immunohistochemically 
with the proliferation marker Ki-67. Placebo-treated tumors 
had high rates of cell proliferation as determined by the 
relatively high intensity of Ki-67 staining (Figure 6B, lower 
left panel, brown color). Tumors from sorafenib-treated 
mice displayed striking lower levels of Ki-67 (Figure 4B, 
lower right panel). Furthermore, sorafenib-treated tumors 
showed areas of nonproliferative cells interspersed with 
proliferating cells.
We also evaluated the anti-angiogenic properties 
of sorafenib. Analysis of tumor vascularization was 
performed by staining of the mouse endothelial cells with 
an anti-CD31-antibody. The staining showed that vascular-
ization in control tumors was characterized by the speciﬁ  c 
CD31-peroxidase staining of endothelial cells (E) lining 
the inner wall of blood vessels and interspaced in the septa 
(Figure 6C, left panel). These cells were less abundant or 
absent in blood vessels of tumors treated with sorafenib 
(Figure 6C, right panel).
Discussion
Sorafenib is a small multi-target inhibitor that has broad 
spectrum activity against several tyrosine kinases. Although 
initially described as a b-Raf inhibitor, sorafenib inhib-
its the activity of several cell surface receptor tyrosine 
kinases, such as VEGFR-2, FLT-3, c-KIT and PDGFR. 
A constitutive activation of receptor tyrosine kinases is 
a common feature of many types of cancers, particularly 
those of soft tissue origin where their concerted expression 
has been shown to promote tumor growth and survival 
(Zhang et al 2000; Lowinger et al 2002; Kawai et al 2004; 
Tamborini et al 2004; Gee et al 2005; Armistead et al 
2007). As such small molecules which can inhibit one or 
all of these receptor tyrosine kinases may provide a means 
of inhibiting tumor cells by removing positive growth and 
survival signaling. With this in mind, we hypothesized that 
sorafenib would be an ideal candidate as a multi-targeted 
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Figure 4 Sorafenib inhibits activation of Erk and Akt through IGF-1 signaling in 
rhabdomyosarcoma cells. Rhabdomyosarcoma cells were starved for 24 hrs, treated 
with 5 μM sorafenib and stimulated with 50 ng/ml of the appropriate ligand (SCF, 
VEGF, PDGF, FLT-3 or IGF-1) or serum for 30 minutes. Cells were lysed directly in 
loading buffer and immunoblotting of Erk and Akt phosphorylation was performed 
for A) RMS, B) RH30, and C) RD cells using phosphor-speciﬁ  c Erk and Akt antibodies. 
Levels of total Erk and Akt were used as loading controls.
Abbreviations: IGF, insulin-like growth factor; SCF, stem cell factor;   VEGF, vascular 
endothelial growth factor; PDGF, platelet-derived growth factor; FLT3, FMS-like 
tyrosine kinase 3.
Figure 5 Sorafenib inhibits IGF-1-induced cell growth in rhabdomyosarcoma cell lines. 
Rhabdomyosarcoma cells (RMS, RH30, and RD) were grown in the presence or absence 
of serum or IGF, followed by treatment with 5 μM sorafenib for 48 hrs. Cell proliferation 
was estimated using WST-1 proliferation reagent as previously described.
Abbreviation: IGF, insulin-like growth factor.
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Figure 6 Effect of sorafenib on alveolar rhabdomyosarcoma (RMS) tumor xenografts. BALB/c SCID mice were inoculated subcutaneously with RMS cells. When the tumors 
were palpable, the mice were treated with 40, 60, 80 mg/kg body weight sorafenib or placebo per orally for 7 days. At the end point of the experiment, mice were euthanized, 
tumors were excised and ﬁ  xed in formalin and stained immunohistochemically with HTX, Ki-67 and CD31. A) Histogram showing the mean tumor mass at end point of 
experiment of rhabdomyosarcoma xenograft tumors treated with placebo or sorafenib. B) Hematoxilin (HX) and Ki-67 stained formalin-ﬁ  xed parafﬁ  n embedded sections 
of RMS tumors. (N: necrosis, S: septa/ﬁ  brovascular tissue). C) Effect of sorafenib on tumor vascularization of formalin-ﬁ  xed parafﬁ  n-embedded sections of RMS tumors were 
stained with CD31.
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therapy against the growth of several classes of soft tissue 
sarcoma. Cytotoxicity screening on a panel of soft tis-
sue sarcoma cell lines of different histological subtypes 
(rhabdomyosarcomas, synovial sarcomas, Ewing’s 
sarcomas and osteosarcomas) showed that sorafenib was 
indeed a potent inhibitor of cell proliferation. We found that 
alveolar rhabdomyosarcoma, synovial sarcoma and half of 
the Ewing’s sarcoma cell lines tested displayed statistically 
signiﬁ  cant inhibition of cell growth at clinically relevant 
concentrations (5 μM) in vitro.
Receptor tyrosine kinases generally promote cell growth 
by inducing phosphorylation and thus activation of substrate 
molecules, among which Erk, involved in promoting cell 
growth, and Akt, which can mediate cell survival, have been 
most studied. Since all three rhabdomyosarcoma cell lines 
responded to sorafenib, we analyzed the effect of sorafenib 
on inhibition of growth factor-mediated activation of Erk 
and Akt. In the case of rhabdomyosarcoma cells, sorafenib 
inhibited activation of both Erk and Akt in RMS cells in 
response to receptor tyrosine kinase activation by serum. 
Sorafenib also effectively blocked Erk activation in RH30 
and RD cells; however, Akt was still activated in the pres-
ence of serum. The fact that Erk was inhibited suggests 
possible defects speciﬁ  c to the Akt pathway (eg, mutation) 
in these cell lines.
The fact that sorafenib failed to induce high levels of 
apoptosis in all cell lines tested, together with a reduced 
cell proliferation index in the tumor xenografts in the 
tumor cells, suggests in our case at least in part, that the 
anti-growth properties of sorafenib is due to blocking of 
cell proliferation. Since Erk is primarily a down stream 
effector for growth stimulatory signaling it would appear 
that inhibiting Erk activity more so than Akt is important 
for the anti tumor effect of sorafenib. In accordance with 
this a recent study has shown that IGF-1 stimulation of Erk 
phosphorylation in cholangiocarcinoma cells can be blocked 
by sorafenib (Huether et al 2007). In this study the authors 
point out two cell responses to sorafenib treatment, with 
cells either entering cycle arrest or undergoing apoptosis. 
Thus sorafenib would appear to have multiple outcomes 
depending on cell type.
Based on previous studies which show the over 
expression of IGF-1R in several rhabdomyosarcomas, we 
decided to include IGF-1R as a potential target for sorafenib. 
Indeed, we found IGF-1R to be highly over expressed in all 
3 rhabdomyosarcoma cell lines tested in comparison with 
the other receptor tyrosine kinases known to be targeted 
by sorafenib (Figure 3). Using ligand speciﬁ  c activation 
assays, we showed that the IGF-1 ligand, as opposed to other 
growth factor ligands is a potent inducer of Erk and Akt 
activation, more importantly, however, this activation can 
be effectively blocked by pre treatment with sorafenib. Thus 
sorafenib widens its repertoire as a receptor tyrosine kinase 
antagonist by also inhibiting the IGF-1R pathways. Interest-
ingly, our results seem to support the idea that IGF-1R is 
over expressed in these cell lines thus one could envision that 
rhabdomyosarcoma cell lines are hyper responsive to IGF-1 
stimulation, thus by blocking the IGF-1 pathway a major 
growth stimulatory pathway is removed. Whether sorafenib 
inhibits IGF-1R directly by binding to the cell surface recep-
tor or by inhibiting down stream components of the IGF-1R 
pathway such as c-Raf still remains to be determined. In the 
case of VEGFR, PDGFR, c-KIT and FLT-3 sorafenib has 
been shown to directly inhibit receptor autophosphorylation 
and activation upstream of Raf inhibition (Wilhelm et al 
2006). In our case, sorafenib blocked IGF-1-mediated Akt 
activation in two of the three cell lines. Since the Erk and Akt 
pathways branch before c-Raf (a known sorafenib inhibitor) 
it would suggest direct interference with receptor activity in 
the sorafenib-treated cell lines which did not activate Akt. 
The relationship between IGF-1R auto-phosphorylation and 
sorafenib is an area of current research.
Building on this, rhabdomyosarcoma cells have been 
shown to have dependency on IGF signaling (El-Badry 
et al 1990; Minniti et al 1992; Minniti et al 1994; Shapiro 
et al 1994). Down regulation of IGF-1R expression by 
antisense has been shown to alter the malignant phenotype 
of rhabdomyosarcoma cells, resulting in tumor growth 
inhibition both in vitro and in vivo (Shapiro et al 1994). 
Moreover, the chimeric transcription factor, an exclusive 
feature of rhabdomyosarcoma, PAX3/7-FKHR has been 
shown to enhance direct transcriptional activator of the 
IGF-1R gene which may account for the relatively high 
levels of IGF-1R observed in these tumors (Gidding et al 
2000; Barber et al 2002; Thimmaiah et al 2003).
Among the sarcoma cell lines, sorafenib had a 
growth inhibitory effect in soft tissue sarcomas that carry 
translocations but not in osteosarcomas, which typically 
display chaotic chromosome arrangements. The cell growth 
inhibition that we observed in the cell lines of soft tissue 
sarcomas was, however, not associated with the expression 
of cytogenetic markers.
Our in vivo study clearly showed a signiﬁ  cant inhibition 
of rhabdomyosarcoma and synovial sarcoma (data not 
shown) growth. Xenografts of RMS cells gave rise to large, 
highly vascularized tumors characterized by high rates of OncoTargets and Therapy 2008:1 77
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proliferation. In contrast, in mice treated with sorafenib the 
tumors appeared smaller and were characterized by impaired 
tumor vascularization, large necrotic areas advanced to the 
tumor stroma and reduced proliferative capacity, supporting 
the notion that sorafenib can effectively block cell growth. 
These observations indicate that the activity of sorafenib on 
the ﬁ  brovascular tissue may deprive tumor cells of growth 
signaling and impairs vascularization, resulting in tumor cell 
death, and demonstrates that this drug affects both tumor cells 
and stromal cells (endothelial cells). The fact that sorafenib-
treated tumors displayed poor vascularization also suggest 
that anti-angiogenic properties of this drug. We believe that 
in addition to the anti-proliferative effect of sorafenib on the 
rhabdomyosarcoma cells, its effect on the tumor stroma is 
determinant for the growth inhibition of the tumors.
Rhabdomyosarcoma is the most common soft tissue 
sarcoma in children (Bersani et al 2008). Current treatment 
for rhabdomyosarcoma is surgery, chemotherapy and 
radiotherapy. However, resistance to chemotherapy and 
radiation therapy is a limiting factor in the treatment of 
rhabdomyosarcoma, leading to therapeutic failure and limiting 
improved survival in these patients (Kuttesch 1996).
Up to date, the effect of sorafenib in vitro and in vivo 
have not been evaluated on rhabdomyosarcomas. Our 
results presented in this paper show that sorafenib can 
inhibit cell proliferation both in vitro and in vivo through 
the inhibition of IGF-1R-mediated signaling, and through 
impaired vascularization, indicating that patients with 
rhabdomyosarcoma that over express IGF-1R may be good 
candidates for treatment with sorafenib.
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